Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study comparing two administration methods of non-pegylated G-CSF for secondary prevention of severe neutropenia
2007-000818-36Phase 3Active
- Sponsor
- Centre Antoine Lacassagne
- Start
- Apr 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenograstim and filgrastim in Non-hematologic malignancy and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Centre Antoine Lacassagne. Primary endpoint: Incidence of grade 3–4 febrile neutropenia within 6 months. Started Apr 2007; status: active.
02
Drugs
lenograstimfilgrastim
03
Conditions
Non-hematologic malignancychemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2007-000818-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000818-36.